Equities Analysts Set Expectations for Geron Q3 Earnings

Geron Corporation (NASDAQ:GERN) – Wedbush lowered their Q3 2026 earnings estimates for shares of Geron in a research note issued on Wednesday, November 5th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q4 2026 earnings at $0.01 EPS.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The company had revenue of $47.23 million during the quarter, compared to analyst estimates of $55.24 million.

Several other research analysts have also commented on the company. Needham & Company LLC cut their price objective on Geron from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday. The Goldman Sachs Group began coverage on shares of Geron in a research note on Thursday, July 10th. They issued a “sell” rating and a $1.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Friday, October 31st. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.64.

Geron Price Performance

Shares of NASDAQ GERN opened at $1.08 on Thursday. The stock’s 50-day simple moving average is $1.30 and its two-hundred day simple moving average is $1.36. Geron has a twelve month low of $1.04 and a twelve month high of $4.50. The firm has a market capitalization of $689.06 million, a P/E ratio of -8.31 and a beta of 0.57. The company has a quick ratio of 6.79, a current ratio of 7.87 and a debt-to-equity ratio of 0.46.

Institutional Trading of Geron

Several hedge funds have recently added to or reduced their stakes in GERN. Frisch Financial Group Inc. boosted its position in Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 8,700 shares during the period. StoneCrest Wealth Management Inc. bought a new stake in shares of Geron in the 2nd quarter valued at about $35,000. Savant Capital LLC boosted its holdings in Geron by 73.8% during the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 11,074 shares during the period. Summit Financial Strategies Inc. purchased a new stake in Geron during the 2nd quarter valued at about $38,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in Geron during the 1st quarter worth approximately $39,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.